InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.400 0.035 (9.59%)+
Announcement
Release
11 Jun 2026 9:46AM
Price at Release
$0.365
Full Release
download
Summary
Island Pharmaceuticals Limited is focused on advancing two clinical stage programs targeting infectious diseases: Galidesivir and ISLA-101. Galidesivir, a small molecule with broad antiviral activity, continues to develop with significant funding from the US government. ISLA-101 has completed a Phase 2a/b clinical trial and shows promise against dengue and other mosquito-borne viruses. Both assets hold the potential for Priority Review Vouchers, enabling faster market entry. The company's robust financial position supports further development of these programs. Island Pharmaceuticals is actively pursuing the FDA Animal Rule pathway for faster approval, especially for Galidesivir as a countermeasure against multiple filovirus threats.
Key Points
  • Two well-advanced clinical programs targeting infectious diseases
  • Phase 2a/b PROTECT clinical trial in dengue completed
  • Potential for Priority Review Vouchers
  • Significant funding and collaboration with US government agencies
  • Galidesivir and ISLA-101 target broad antiviral threats
  • Robust financial position with no debt
  • Utilizing FDA Animal Rule for expedited approval pathways
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.